References
- Storz U. IP Issues of Therapeutic Antibodies. In: Storz (ed), SpringerBriefs in Biotech Patents: “Intellectual Property Issues: Therapeutics, Vaccines and Molecular Diagnostics”, 2012, 1-16.
- DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: Is biotech different?. Manage Decis Econ 2007; 28:469 - 79; http://dx.doi.org/10.1002/mde.1360
- Grabowski H, Cockburn I, Long G. The market for follow-on biologics: how will it evolve?. Health Aff (Millwood) 2006; 25:1291 - 301; http://dx.doi.org/10.1377/hlthaff.25.5.1291; PMID: 16966725
- Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 7; http://dx.doi.org/10.1038/256495a0; PMID: 1172191
- Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40:3147 - 54; PMID: 7427932
- Reff ME. The Discovery of Rituxan, in: Smith, C. G., O'Donnell, J. (Eds.), The process of new drug discovery and development. 2nd edition ed. Informa Healthcare, New York, 2006, 565-584.
- Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, Sleeman MA, Davis DM. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood 2013; 121:4694 - 702; http://dx.doi.org/10.1182/blood-2013-02-482570; PMID: 23613524
- Van Allen EM, Miyake T, Gunn N, Behler CM, Kohlwes J. Off-label use of rituximab in a multipayer insurance system. J Oncol Pract 2011; 7:76 - 9; http://dx.doi.org/10.1200/JOP.2010.000042; PMID: 21731512
- Bomm L, Fracaroli TS, Sodré JL, Bressan A, Gripp AC. Off-label use of rituximab in dermatology: pemphigus treatment. An Bras Dermatol 2013; 88:676 - 8; http://dx.doi.org/10.1590/abd1806-4841.20131905; PMID: 24068154
- ex. rel. Underwood vs Genentech, Civil Action No. 03-3983, District Court for the Eastern District of Pennsylvania.
- Eisenstein M. Approval on a knife edge. Nat Biotechnol 2012; 30:26 - 9; http://dx.doi.org/10.1038/nbt.2084; PMID: 22231087
- Beach & Strehlow, in: Steiner, Clinical Research Law And Compliance Handbook, Jones and Bartlett Publishers, 2006, 265-299.
- Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today 2012; 17:660 - 4; http://dx.doi.org/10.1016/j.drudis.2012.02.005; PMID: 22366309
- EPA Technical Board of Appeal decision T0007/07.
- Genentech vs. Columbia, N.D. Cal. 2003, Case No 3:03-cv-01603.
- Genentech vs. GlaxoWellcome, D. Delaware, Case No. 99-335-RRM.
- Storz U. The Cabilly patents: Status quo and relevance for antibody companies. MAbs 2012; 4:274 - 80; http://dx.doi.org/10.4161/mabs.4.2.19253; PMID: 22453097
- GSK vs. Genentech, ND. California, Case No 5:10-cv-04255-PVT.
- IDEC vs. Corixa, SD. California, Case No P-01-1637 (RFC)
- Biogen vs. GSK, Case no 3:2010cv00608.
- Appeal No. 2012-1120 Fed. Cir. Apr. 16, 2013.
- Sandercock CG, Storz U. Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope. Nat Biotechnol 2012; 30:615 - 8; http://dx.doi.org/10.1038/nbt.2291; PMID: 22781681
- Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013; 5:621 - 3; http://dx.doi.org/10.4161/mabs.25864; PMID: 23924791
- Reichert JM. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany. MAbs 2011; 3:223 - 40; http://dx.doi.org/10.4161/mabs.3.3.15475; PMID: 21487235
- Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012; 5:64 - 72; http://dx.doi.org/10.1186/1756-8722-5-64; PMID: 23057966
- Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, French RR, Glennie MJ. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101:1045 - 52; http://dx.doi.org/10.1182/blood-2002-06-1761; PMID: 12393541